Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 4, July, p. 587–594

doi: 10.17219/acem/62454

PubMed ID: 28691425

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Tolerance of combined radiochemotherapy in cervical cancer patients

Barbara Izmajłowicz1,2,A,B,C,D, Małgorzata Rusiecka1,2,B, Aleksandra Sztuder2,B,C,D, Marcin Stępień1,2,B, Agnieszka Ignatowicz-Pacyna1,2,B, Beata Słocka-Romaniuk1,2,B, Zbigniew Mazur1,2,B, Jan Kornafel1,2,A,E,F

1 Department of Oncology, Gynaecological Oncology Clinic, Wroclaw Medical University, Poland

2 Clinical Department of Gynecological Radiotherapy Lower Silesian Cancer Center, Wrocław, Poland

Abstract

Background. Radiochemotherapy in cervical cancer was implemented to clinical practice based on 5 randomized clinical trials, published at the end of the 20th century, which showed improvement in the total and symptomless survivals by about 10–18%. The increase of therapeutic index of such treatment can take place only when the efficiency of the treatment outweighs the increase of its toxicity. Thus, it is necessary to monitor treatment reaction during radiochemotherapy.
Objectives. The aim of this study was to assess the acute post-radiation reaction during radiochemotherapy for cervical cancer and the to analyze the reasons of the unplanned course of combined treatment.
Material and Methods. A group of consecutive 176 cervical cancer patients in the clinical stage from IB to IIIB acc. to FIGO classification who underwent radiochemotherapy were taken under prospective observation in Clinical Gynecologic Radiotherapy Ward of the Lower Silesian Cancer Center in Wrocław between April 2010 and September 2012. Early post-radiation reaction was assessed in RTOG/EORTC scale once a week.
Results. During the treatment early post-radiation reaction of upper part of alimentary duct was observed in 74.4% of the patients, the reaction of lower part of gastrointestinal tract in 51.2%, and in bladder 44.8%. The most frequent symptoms of post-radiation reaction are: nausea (73.3% of the patients), diarrhea (51.2%) and vomiting (20.9%). Leucopenia was observed in 97.1% of the patients, granulocytopenia in 70.4%, anemia in 69.2%, and thrombocytopenia in 25.5%. The planned dose of radiotherapy was administered completely in 90.1% of the patients. A break in radiotherapy was necessary in 15.7% of the patients. In total, 44.8% of the patients did not receive radiochemotherapy according to the plan, because of the side effects of the treatment (most often leucopenia, thrombocytopenia and gastrointestinal reaction).
Conclusion. The presented data shows that radiochemotherapy causes the intensification of acute side effects of treatment and may cause unplanned course of treatment and prolongation of the total treatment time.

Key words

combined treatment, cervical carcinoma, radiochemotherapy, radiation tolerance

References (42)

  1. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie. Available from: http://onkologia.org.pl/raporty/, accessed on 06.12.2015
  2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 11.12.2015
  3. Peters W, Liu P, Barrett R, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–1613.
  4. Keys H, Bundy B, Stehman F, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky Ib cervical carcinoma. N Engl J Med. 1999;340:1154–1167.
  5. Whitney C, Sause W, Bundy B, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol. 1999;17:1339–1348.
  6. Rose P, Bundy B, Watkins E, et al. Concurrent cisplatin- based radiotherapy and chemiotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–1153.
  7. Morris M, Eifle P, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high risk cervical cancer. N Engl J Med. 1999;340:1137–1143.
  8. NCCN, National Comprehensive Cancer Network, Practice Guidelines in Oncology- V. I. 2016: http://www. nccn.org/proffesionals/physicians.
  9. Krzakowski M., Warzocha K. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2013 rok. Via Medica Gdańsk, 2013.
  10. Jassem J. Postępy w skojarzonym leczeniu nowotworów z udziałem radioterapii i chemioterapii. Nowotwory. 2000;50:12–20.
  11. Steel GG. Basic Clinical Radiobiology. Arnold, London, 2002.
  12. Bentzen SM, Harari PM, Bernier J. Exploitable mechanisms for combining drugs with radiation: Concepts, achievements and future directions. Nat Clin Pract Oncol. 2007;4:172–180.
  13. Błaszczyk J, Jagas M, Bębenek M. Przeżycia 5-letnie chorych na nowotwory złośliwe z lat 1985-2004 w woj. Dolnośląskim. Dolnośląski Rejestr Nowotworów, Wrocław 2011.
  14. Wojciechowska U, Didkowska J, Zatoński W. Pięcioletnie przeżycia chorych na nowotwory złośliwe w Polsce. Nowotwory. 2010;60:122–129.
  15. Green J, Kirwan J, Tierney J, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet. 2001;358:781–786.
  16. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiotion therapy for cancer of the uterine cervix. Cohrance Database Syst Rev. 2005;20:3.
  17. Lukka H, Hirte H, Fyles A, et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer- a meta-analysis. Clin Oncol. 2002;14:203–212.
  18. Kirwan J, Symonds P, Green, J, et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol. 2003;68:217–226.
  19. Kumaran A, Guruvare S, Sharan K, et al. Chemoradiation related acute morbidity in carcinoma cervix and correlation with hematologic toxicity: A South Indian prospective study. Asian Pac J Cancer Prev. 2014;15(11):4483–4486.
  20. Eifel PJ. Chemoradiotherapy in the treatment of cervical cancer, Semin Radiat Oncol. 2006;16:177.
  21. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20:966.
  22. Van de Bunt L, van der Heide U, Ketelaars M, et al. Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression. Int J Radiat Oncol Biol Phys. 2006;64:189–196.
  23. Bednaruk-Młyński E, Senkus-Konefka E, Górzyński M, et al. Paralel-oposed fields vs. four fields, and two-(2D) vs. three-dimensional (3D) radiotherapy planning in thin patients with gynecological malignancies. Reports of practical oncology and radiotherapy. 2003;8(supl 2):242.
  24. Heron D, Gerszten K, Selvaraj R, et al. Conventional 3D versus intensity modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: A comparative dosimetric study of dose-volume histograms small star, filled. Gynecol Oncol. 2003;91:39–45.
  25. Gandhi AK, Sharma DN, Rath GK, et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: A prospective randomized study. Int J Radiat Oncol Biol Phys. 2013;87:542–548.
  26. Hui B, Zhang Y, Shi F, et al. Association between bone morrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: Comparison of tree- dimensional conformal radiotherapy and intensity- modulated radiation therapy. Int J Gynecol Cancer. 2014;24:1648–1652.
  27. Simpson DR, Song WY, Moiseenko V, et al. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin. Int J Radiat Oncol Biol Phys. 2012;83:81–86.
  28. Erpolat OP, Alco G, Caglar HB, et al. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: A national multi- center study. Eur J Gynaecol Oncol. 2014;35:62–66.
  29. Nag S, Erickson B, Thomadsen B, et al. The American Brachyterapy Society Recommendation for High Dose Rate Brachyterapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000;48:201.
  30. Perez CA, Grigsby PW, Castro-Vita H, et al. Carcinoma of the uterine cervix. Impact of prolongation of overall treatment time and timing of brachyterapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1995;32:1275.
  31. Petereit DG, Sarkaria JN, Hartmann TJ, et al. Adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys. 1995;32:1301.
  32. Shaverdian N, Gondi V, Sklenar KL, et al. Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2013;86:562–568.
  33. Toita T, Kitagawa R, Hamano T, et al. Feasibility and acute toxicity of concurrent chemoradiotherapy (CCRT) with high- dose rate intracavitary brachytherapy (HDR- ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: Results of a multi- institutional phase 2 study (JGOG 1066). Int J Gynecol Cancer. 2012;22:1420–1426.
  34. Tan LT, Russell S, Burgess L. Acute toxicity of chemo-radiotherapy for cervical cancer: The Addenbrooke’s experience. Clin Oncol. 2004;16:255–260.
  35. Krusun S, Pesee M, Supakalin N, et al. Treatment interruption during concurrent chemoradiotherapy of uterine cervical cancer; analysis of factors and outcomes. Asian Pac J Cancer Prev. 2014;15:5653–5657.
  36. Nugent EK, Case AS, Hoff JT, et al. Chemoradiation in locally advanced cervical carcinoma: An analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol. 2010;116:438–441.
  37. Winter WE, Maxwell GL, Tian C, et al. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: A Gynecologic Oncology Group Study. Gynecol Oncol. 2004;94:495.
  38. Choi YS, Yi CM, Sin JI, et al. Impact of hemoglobin on survival cervical carcinoma patients treated with concurrent chemoradiotherapy is dependent on lymph node metastasis findings by magnetic resonance imaging. Int J Gynecol Cancer. 2006;16:1846
  39. Ferrandina G, Distefano M, Smaniotto D, et al. Anemia in patients with advanced cervical carcinoma administered preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome. Gynecol Oncol. 2006;103:500
  40. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86:1528.
  41. Thomas G. The effect of hemoglobin level on radiotherapy outcomes: The Canadian experience. Semin Oncol. 2001;28:60.
  42. Jakubowicz J, Blecharz P, Skotnicki P, et al. Toxicity of concurrent chemoradiotherapy for locally advanced cervical cancer. Eur J Gynaecol Oncol. 2014;35:393–399.
© Wroclaw Medical University